CoChat

Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer

Open access

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

We previously reported that elevated levels of diazepam binding inhibitor (DBI), also called ‘endozepine’ because it acts as an endogenous benzodiazepine equivalent on the gamma-aminobutyric acid type A receptor, constitutes a potential risk factor for the diagnosis of non-small cell lung cancer (NSCLC). Antibody-mediated neutralization of DBI improved the immunosurveillance of NSCLC in preclinical models with and without immunotherapy targeting programmed cell death protein 1 (PD-1). A pilot study in a small French-Canadian cohort (n = 205) suggested that benzodiazepine (BZD) use correlates with reduced progression-free survival in NSCLC patients receiving PD-1/PD-L1 blockade. Here, we report a retrospective analysis of the nation-wide French registry of advanced NSCLC patients treated with pembrolizumab. Among the eligible NSCLC patients surviving ≥2 months after treatment initiation (n = 31,479), 37.7% (n = 11,878) received at least two prescriptions of benzodiazepines within 90 days before to 30 days after treatment initiation. Compared to non-users (n = 19,601), BZD users had significantly reduced overall survival (hazard ratio = 1.08, 95% CI: 1.04–1.12, p < 0.001), an effect that persisted after correction using inverse probability of treatment weighting (IPTW) on sociodemographic, clinical, oncologic, and comedication variables. In a subset of 556 patients from the ONCOBIOTICS study, benzodiazepine use was associated with signs of intestinal dysbiosis and alterations in the TOPOSCORE, a prognostic marker linked to poorer outcomes in cancer patients receiving immunotherapy. We conclude that benzodiazepine use may be an independent negative prognostic factor for NSCLC patients under pembrolizumab-based immunotherapy. Future studies must determine whether withdrawal of benzodiazepines or neutralization of DBI improves the clinical response to immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2025.2528955

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Impact of benzodiazepines on overall survival of lung cancer patient under pembrolizumab-based immunotherapy in the French national database including patients with non-small cell lung cancer that received immunotherapy. The graph compares the survival of patients after the 2 month-landmark that received benzodiazepines (orange line) or not (blue line). The number of surviving patients is indicated below the graph for selected time points.
Figure 1. Impact of benzodiazepines on overall survival of lung cancer patient under pembrolizumab-based immunotherapy in the French national database including patients with non-small cell lung cancer that received immunotherapy. The graph compares the survival of patients after the 2 month-landmark that received benzodiazepines (orange line) or not (blue line). The number of surviving patients is indicated below the graph for selected time points.CC BY · PubMed Central
Figure 2. Impact of benzodiazepine and antibiotic use on overall survival of patients enrolled in the ONCOBIOTICS trial.
Figure 2. Impact of benzodiazepine and antibiotic use on overall survival of patients enrolled in the ONCOBIOTICS trial.CC BY · PubMed Central
Figure 3. Impact of benzodiazepine and antibiotic use on the fecal microbiota in patients enrolled in the ONCOBIOTICS trial.
Figure 3. Impact of benzodiazepine and antibiotic use on the fecal microbiota in patients enrolled in the ONCOBIOTICS trial.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 8

Metadata

Authors
Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., & Kroemer, G.
Affiliations
  • Inserm (FR)
  • Université Paris-Saclay (FR)
  • Université Paris-Saclay
  • Centre Hospitalier de l’Université de Montréal (CA)
  • University of Naples Federico II (IT)
Corresponding author
  • Pasolli, Edoardo
  • Kroemer, Guido
Venue
OncoImmunology
Published
2025-07-04
Volume
14
Issue
1
Pages
2528955-2528955
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W4412034547
Cited by
8
References
67
Citations by year
2026: 6 · 2025: 2
FWCI
3.31
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Gustave Roussy Foundation
  • European Union’s Horizon 2020 research and innovation program
  • French Ministry of Health PIA5
  • SIGN’IT ARC Foundation (MICROBIONT-PREDICT (2021))
  • European Research Council (ERC-2023-ADG - MADCAM – 101142062, ERC-2021-ADG)
  • IHMCSA (964590)
  • Institut National du Cancer (INCA_ 16698)
  • Ligue contre le Cancer
  • Agence National de la Recherche (ANR-22-CE14-0066)
  • Association pour la recherche sur le cancer
  • Cancéropôle Ile-de-France
  • Fondation pour la Recherche Médicale
  • Elior
  • European Joint Program on Rare Diseases
  • European Union Horizon 2020 research and innovation programmes
  • Agence Nationale de la Recherche (21-ESRE-0028)
  • Hevolution Network on Senescence in Aging (HF-E Einstein Network)
  • Institut Universitaire de France
  • LabEx Immuno-Oncology
  • Seerave Foundation
  • SIRIC Cancer Research and Personalized Medicine (CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006)
  • IdEx Université de Paris Cité
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
benzodiazepines, pembrolizumab, non-small cell lung cancer, cancer immunotherapy, diazepam binding inhibitor, endozepines, PD-1/PD-L1 blockade, overall survival, prognostic factors, gut dysbiosis, GABAA receptor, drug-drug interactions
MeSH terms
Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Benzodiazepines, Carcinoma, Non-Small-Cell Lung, Female, France, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer. https://app.cochat.ai/papers/10.1080/2162402x.2025.2528955
The paper
Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., & Kroemer, G. (2025). Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer. OncoImmunology. https://doi.org/10.1080/2162402x.2025.2528955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.